Absci (ABSI) vs Maze Therapeutics (MAZE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Absci (ABSI) has outperformed Maze Therapeutics (MAZE) over the past year, gaining 153.4% versus a loss of 5.7%. Absci is the larger company by market cap ($1.74 billion vs $1.51 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABSI | MAZE |
|---|---|---|
| Share price | $10.16 | $27.11 |
| Market cap | $1.74B | $1.51B |
| 1-day change | +13.65% | +4.75% |
| YTD return | +191.12% | -34.56% |
| 1-year return | +153.37% | -5.74% |
| 5-year return | -4.42% | — |
| EPS (TTM) | $-0.79 | $-2.60 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.80M | — |
| Revenue growth (YoY) | -38.24% | — |
| Net income (latest FY) | $-115.18M | $-131.12M |
| Operating margin | -4297.04% | — |
| Net margin | -4113.68% | — |
| 52-week high | $12.06 | $53.65 |
| 52-week low | $2.24 | $21.95 |
| Distance from 52-week high | -15.72% | -49.47% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +41.73% | +126.85% |
| Average volume | 3.43M | 565.24K |
| Shares outstanding | 171.61M | 55.55M |
| Employees | 140 | 141 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABSI has outperformed MAZE by 159.1 percentage points over the past year.
About Absci
ABSI stock →Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 140 employees
About Maze Therapeutics
MAZE stock →Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees
ABSI vs MAZE FAQ
Which is bigger, Absci or Maze Therapeutics?
Absci (ABSI) is larger, with a market capitalization of $1.74B compared with $1.51B for Maze Therapeutics (MAZE).
Which stock has performed better over the past year, ABSI or MAZE?
ABSI returned +153.37% over the past 12 months, compared with -5.74% for MAZE (price return, excluding dividends). Past performance does not predict future results.
Are Absci and Maze Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Commercial Physical & Biological Resarch for Absci and Biotechnology: Biological Products (No Diagnostic Substances) for Maze Therapeutics.